Shanghai RAAS's controlling shareholder announces increased stake plan

Shanghai RAAS Blood Products (SZSE:002252) announced that its controlling shareholder, Sea Harbour Healthcare (Qingdao) Medical Technology Co., Ltd., intends to increase its shareholding in the company. The plan will see Sea Harbour Healthcare invest between CNY 250 million and CNY 500 million (inclusive of the stated amounts but excluding transaction costs) in Shanghai RAAS shares over the next six months, using its own funds and a dedicated shareholding loan, where the loan portion shall not exceed 90%. The move reflects Sea Harbour Healthcare's confidence in Shanghai RAAS's long-term prospects and aims to bolster investor confidence. As of May 19, 2025, Sea Harbour Healthcare directly holds 22.21% of Shanghai RAAS and controls a total of 28.80% of the voting rights. The share increase will be conducted through the Shenzhen Stock Exchange trading system, using a centralized competitive bidding approach.